Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback